Comparing two techniques of panretinal photocoagulation on visual acuity on patients with proliferative diabetic retinopathy

Department of Ophthalmology, Clinical Hospital Center Split, Split, Croatia.
Medical Archives 10/2012; 66(5):321-3. DOI: 10.5455/medarh.2012.66.321-323
Source: PubMed


We wanted to examine which of two panretinal photocoagulation (PRP) techniques, classical panretinal photocoagulation (CPRP) and modifield peripheral panretinal photocoagulation PPRP), causes less decline of visual acuity (VA) due to macular edema (ME) in patients with proliferative diabetic retinopathy (PRD). This clinical study includes 180 eyes with PDR with initial papillar neovascularization. The patients were divided into two groups according the RP. PPRP and CPRP showed the decline of VA in all patients, more pronounced in the CPRP group after one week. After three and six months, with CPRP and PPRP the values of VA was stabilized. The result suggests that eyes with PDR and starting epipapillar neovascularisation should be treated with PPRP with priority given to CPRP because it caused better VA.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors reviewed the preoperative, postoperative, and follow-up examinations, fundus photographs, and fluorescein angiograms of 175 eyes with proliferative diabetic retinopathy treated with panretinal photocoagulation. Seventy-five (43%) of the treated eyes developed increased macular edema 6-10 weeks following laser treatment. Follow-ups ranged from 3 months to 48 months, with a median follow-up of 15 months. Fluorescein angiography revealed that the postlaser increase in macular edema persisted in 47 of the 175 eyes (27%). Fourteen eyes (8%) treated with laser developed chronic macular edema and visual loss of two or more lines. Inflammation and altered retinal blood flow are possible pathogenetic mechanisms responsible for the development of postpanretinal photocoagulation macular edema.
    Retina 01/1985; 5(1):5-10. DOI:10.1097/00006982-198500510-00002 · 3.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare macular thickness and best-corrected visual acuity (BcVA) before and after panretinal photocoagulation (PRP) in patients with severe diabetic retinopathy and good visual acuity (VA) to identify factors that predict post-operative visual function. Prospective, non-comparative, interventional case series. Sixty-four consecutive patients with severe non-proliferative diabetic retinopathy or with non-high-risk proliferative diabetic retinopathy whose VA was 20/20 or better before PRP were studied. Sixty-four eyes of 64 patients underwent scatter PRP in four sessions every other week. Macular thickness was measured by optical coherence tomography (OCT), and VA was measured before and periodically after PRP. During the 24-week observation period, patients were classified into three groups according to changes in VA during the post-operative period. In group A, VA was maintained at pre-operative levels in 54 (84%) eyes during the 24 weeks after PRP. In group B, VA initially decreased in three eyes but subsequently recovered to baseline during the observation period; in group C, VA did not recover during follow-up in seven eyes. There was no significant difference in pre-operative foveal thicknesses among the three groups, but parafoveal thickness was <260 mum in group A, ranged from 270 to 280 mum in group B, and was >300 mum in group C. For eyes with severe diabetic retinopathy and good VA, PRP did not affect post-operative VA in more than 80% of patients. Patients whose pre-operative parafoveal thickness was >300 mum had a worse visual prognosis.
    American Journal of Ophthalmology 08/2005; 140(1):8-15. DOI:10.1016/j.ajo.2005.02.029 · 3.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Diabetic Retinopathy Study (DRS) demonstrated that prompt argon laser photocoagulation, in comparison to indefinite delay in treatment, could reduce by more than 50% the risk of severe visual loss from proliferative diabetic retinopathy. The DRS also enlightened two generations of ophthalmologists about the value of the randomized controlled clinical trial as a way of assessing new and existing treatments for unsolved therapeutic problems. After the example of the DRS, laser treatment was shown to be effective in reducing vision loss in selected patients with branch retinal vein occlusion, age-related macular degeneration, ocular histoplasmosis, and diabetic macular edema. Existing trials, supported by the National Eye Institute, are seeking to determine the appropriate treatment for selected patients with newly diagnosed glaucoma, vascularized corneas, retinopathy of prematurity, proliferative vitreoretinopathy and complicated retinal detachment, and choroidal melanoma. Clinical practice has benefited enormously from these studies all of which owe their existence, at least in part, to the prototypical clinical trial, the DRS. This symposium discusses the DRS and places it in today's perspective, with a look to the past as well.
    Ophthalmology 08/1987; 94(7):739-40. DOI:10.1016/S0161-6420(87)33523-7 · 6.14 Impact Factor
Show more


5 Reads
Available from